Diabetic patients, particularly those with type 2 diabetes (T2D), are highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced adverse outcomes and complications. The massive global T2D burden and high COVID-19 infection rate is creating large and significantly vulnerable COVID-19 T2D patient populations.
The prevalence of diabetes among admitted COVID-19 infections has varied 20-50% by region.T2D patients are more prone to a severe COVID-19 disease course, marked by dangerous infection-induced adverse outcomes and complications including intensive care unit (ICU) admission, mechanical ventilation use, or death. The clinical experience with patients admitted to the Michigan Medicine COVID-19 Cohort (M2C2, PI: Hayek): 42% of COVID-19 cases had diabetes, and a disproportionally larger fraction, 56%, required ICU admittance and suffered over twice the mortality (22%) compared to non-diabetic (10%) patients. Thus, T2D consistently predisposes COVID-19 patients to poorer prospects, including acute kidney injury, cardiovascular complications and death.
Most T2D patients frequently suffer from comorbidities, including metabolic syndrome (obesity, hypertension), chronic inflammation, and vascular diabetic complications, i.e., diabetic kidney disease (DKD), diabetic neuropathy (DN), and cardiovascular disease (CVD). In the multi-center French Coronavirus SARS-CoV-2 and Diabetes Outcomes (CORONADO) study (n=1,317 diabetic participants, 88.5% T2D), obesity, measured by body mass index (BMI) positively predicted the study primary outcome, tracheal intubation for mechanical ventilation and/or death within 7 days of admission. The presence of micro- and macrovascular complications at admission independently associated with 7-day mortality, as did inflammation [C-reactive protein (CRP)]and liver injury at admission. Thus, T2D patients, through their comorbid conditions, are at an especially dangerous risk of serious COVID-19 infection and death.
The underlying reasons for the T2D patient susceptibility to COVID-19 remains unclear, although there are several theories. One is that COVID-19-induced cytokine storm syndrome (CSS) may superimpose on the chronic inflammation already present in T2D, promoting a vicious cycle of cytokine release and hyperglycemic surges. T2D is characterized by a chronic, low-grade inflammation, which is also a feature of its complications, DKD, DN, and CVD. Importantly, there are no studies stratifying patients by diabetes status to determine whether a biomarker would be especially useful for predicting the clinical course in COVID-19 T2D patients.
It is also becoming clear that COVID-19 survivors may face a lifetime of sequelae. As with acute infection, T2D patients may also be particularly at risk here. Although the pandemic has not yet lasted long enough to measure long term outcomes, the evidence to date suggests a significant burden of new complications. For instance, COVID-19 may aggravate preexisting pathology, including in T2D patients, and multi-organ injury that aggravates tissues already weakened by preexisting diabetic complications. Finally, the COVID-19 pandemic has seen racial health disparities soar. SARS outbreak survivors report long term effects, even years later, including psychological and financial hardship. In addition, given the disparity during the COVID-19 pandemic, racial minorities faced even more hardships. Identifying these psychosocial factors could mitigate long term psychological trauma. The challenges of the long-term consequences of COVID-19 are emerging as a growing number of patients are long-term survivor sequelae. Identifying these COVID-19 patients who experienced serious clinical complications during their inpatient hospitalization and then sequelae after the acute phase, will deliver better long term outpatient care and allow to preemptively screen for new onset and progression in all complications.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
